Osteoprotegerin as a marker of atherosclerosis in diabetic patients

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Augoulea, Areti ^a,b   Vrachnis, Nikolaos ^a,b   Lambrinoudaki, Irene ^a   Dafopoulos, Konstantinos ^c   Iliodromiti, Zoe ^a   Daniilidis, Angelos ^d   Varras, Michail ^e   Alexandrou, Andreas ^f   Deligeoroglou, Efthymios ^a   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^e General District Hospital Helena Venizelou   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CAROTID ARTERY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; EPICORONARY ARTERY STENOSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PULSE WAVE; REVIEW; SILENT MYOCARDIAL ISCHEMIA; SUBCLINICAL ATHEROSCLEROSIS;

EID: 84873370469     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/182060     Document Type: Review

References (70)

1. Venuraju S. M., Yerramasu A., Corder R., Lahiri A., Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. Journal of the American College of Cardiology 2010 55 19 2049 2061 2-s2.0-77951645187 10.1016/j.jacc.2010.03.013
2. Carnevale V., Romaglino E., D'Erasmo E., Skeletal involvement in patients with diabetes mellitus. Diabetes/Metabolism Research and Reviews 2004 20 3 196 204 2-s2.0-2642565953 10.1002/dmrr.449 (Pubitemid 38714317)
3. Valerio G., Del Puente A., Esposito del Puente A., Buono P., Mozzillo E., Franzese A., The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Hormone Research 2002 58 6 266 272 2-s2.0-0036438958 10.1159/000066441 (Pubitemid 35404237)
4. Heap J., Murray M. A., Miller S. C., Jalili T., Moyer-Mileur L. J., Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. Journal of Pediatrics 2004 144 1 56 62 2-s2.0-0346494432 10.1016/j.jpeds.2003.10.066 (Pubitemid 38091422)
5. Chen N. X., Moe S. M., Arterial calcification in diabetes. Current Diabetes Reports 2003 3 1 28 32 2-s2.0-0037314506 (Pubitemid 38906762)
6. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., Nishizawa Y., Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 106 10 1192 1194 2-s2.0-0037015255 10.1161/01.CIR.0000031524.49139.29 (Pubitemid 34988634)
7. Schoppet M., Sattler A. M., Schaefer J. R., Herzum M., Maisch B., Hofbauer L. C., Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism 2003 88 3 1024 1028 2-s2.0-0037338946 10.1210/jc.2002-020775 (Pubitemid 36337751)
8. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S. A., Jain T., Gruntmanis U., McGuire D. K., de Lemos J. A., Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). American Journal of Cardiology 2007 99 4 513 518 2-s2.0-33846838864 10.1016/j.amjcard. 2006.08.064 (Pubitemid 46215559)
9. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., Willeit J., Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004 109 18 2175 2180 2-s2.0-2442492972 10.1161/01.CIR.0000127957.43874.BB (Pubitemid 38625393)
10. Ali Z., Ellington A. A., Mosley T. H., Kullo I. J., Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis 2009 206 2 575 580 2-s2.0-70349429734 10.1016/j.atherosclerosis.2009.03.032
11. Shargorodsky M., Boaz M., Luckish A., Matas Z., Gavish D., Mashavi M., Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009 204 2 608 611 2-s2.0-67349212618 10.1016/j.atherosclerosis.2008.10.024
12. Nybo M., Rasmussen L. M., The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. European Journal of Endocrinology 2008 159 5 603 608 2-s2.0-56749173769 10.1530/EJE-08-0554
13. Gannagé-Yared M. H., Yaghi C., Habre B., Khalife S., Noun R., Germanos-Haddad M., Trak-Smayra V., Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. European Journal of Endocrinology 2008 158 3 353 359 2-s2.0-40949106785 10.1530/EJE-07-0797 (Pubitemid 351405000)
14. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J. P., Dupuy A. M., Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005 28 9 2176 2180 2-s2.0-24144488713 10.2337/diacare.28.9.2176 (Pubitemid 41242464)
15. Xiang G. D., Xu L., Zhao L. S., Yue L., Hou J., The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006 55 7 2126 2131 2-s2.0-33747082431 10.2337/db06-0231 (Pubitemid 44509988)
16. Galluzzi F., Stagi S., Salti R., Toni S., Piscitelli E., Simonini G., Falcini F., Chiarelli F., Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. European Journal of Endocrinology 2005 153 6 879 885 2-s2.0-29644447888 10.1530/eje.1.02052 (Pubitemid 43020239)
17. Lane H. A., Smith J. C., Davies J. S., Noninvasive assessment of preclinical atherosclerosis. Vascular Health and Risk Management 2006 2 1 19 30 2-s2.0-33646074295 10.2147/vhrm.2006.2.1.19
18. Mack W. J., Labree L., Liu C. R., Liu C. H., Selzer R. H., Hodis H. N., Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis 2000 150 2 371 379 2-s2.0-0034036476 10.1016/S0021-9150(99)00383-4 (Pubitemid 30336549)
19. Bots M. L., Hoes A. W., Koudstaal P. J., Hofman A., Grobbee D. E., Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96 5 1432 1437 2-s2.0-0030826182 (Pubitemid 27375333)
20. Singh T. P., Groehn H., Kazmers A., Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. Journal of the American College of Cardiology 2003 41 4 661 665 2-s2.0-0037454013 10.1016/S0735-1097(02)02894-2 (Pubitemid 36223334)
21. Järvisalo M. J., Raitakari M., Toikka J. O., Putto-Laurila A., Rontu R., Laine S., Lehtimäki T., Rönnemaa T., Viikari J., Raitakari O. T., Endothelial dysfunction and increased arterial iIntima-media thickness in children with type 1 diabetes. Circulation 2004 109 14 1750 1755 2-s2.0-8144230928 10.1161/01.CIR.0000124725.46165.2C (Pubitemid 38500678)
22. Järvisalo M. J., Jartti L., Näntö-Salonen K., Irjala K., Rönnemaa T., Hartiala J. J., Celermajer D. S., Raitakari O. T., Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 2001 104 24 2943 2947 2-s2.0-0035846615 (Pubitemid 33139107)
23. Rasmussen L. M., Ledet T., Osteoprotegerin and diabetic macroangiopathy. Hormone and Metabolic Research 2005 37 1 S90 S94 2-s2.0-20444455081 10.1055/s-2005-861371 (Pubitemid 40813900)
24. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H. L., Trall G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W. J., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 2 309 319 2-s2.0-0031005576 (Pubitemid 27199902)
25. Fu M., Zhang J., Lin Y., Zhu X., Willson T. M., Chen Y. E., Activation of peroxisome proliferator-activated receptor γ inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochemical and Biophysical Research Communications 2002 294 3 597 601 2-s2.0-0036288940 10.1016/S0006-291X(02)00533-8 (Pubitemid 34694051)
26. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., Chen Y. E., PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Letters 2002 521 1-3 180 184 2-s2.0-0037134852 10.1016/S0014-5793(02)02872-7 (Pubitemid 34628481)
27. Malyankar U. M., Scatena M., Suchland K. L., Yun T. J., Clark E. A., Giachelli C. M., Osteoprotegerin is an (v) β 3-induced, NF- B-dependent survival factor for endothelial cells. Journal of Biological Chemistry 2000 275 28 20959 20962 2-s2.0-0034647341 10.1074/jbc.C000290200 (Pubitemid 30481782)
28. Olesen P., Ledet T., Rasmussen L. M., Arterial osteoprotegerin: Increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF- Diabetologia 2005 48 3 561 568 2-s2.0-16844385959 10.1007/s00125-004-1652-8 (Pubitemid 40487304)
29. Collin-Osdoby P., Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research 2004 95 11 1046 1057 2-s2.0-9344246863 10.1161/01.RES.0000149165.99974.12 (Pubitemid 39557891)
30. Ovchinnikova O., Gylfe A., Bailey L., Nordstrom A., Rudling M., Jung C., Bergström S., Waldenström A., Hansson G. K., Nordström P., Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 10 1478 1480 2-s2.0-70349568748 10.1161/ATVBAHA.109.188185
31. Morony S., Tintut Y., Zhang Z., Cattley R. C., Van G., Dwyer D., Stolina M., Kostenuik P. J., Demer L. L., Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008 117 3 411 420 2-s2.0-38349133382 10.1161/CIRCULATIONAHA.107.707380
32. Breland U. M., Hollan I., Saatvedt K., Almdahl S. M., Damas J. K., Yndestad A., Mikkelsen K., Førre Ø. T., Aukrust P., Ueland T., Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. Rheumatology 2010 49 6 1118 1127 2-s2.0-77953505287 10.1093/rheumatology/keq005
33. Cummings S. R., San Martin J., McClung M. R., FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine 2009 361 8 756 765
34. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., Simonet W. S., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 9 1260 1268 2-s2.0-0032079445 (Pubitemid 28213402)
35. Bennett B. J., Scatena M., Kirk E. A., Rattazzi M., Varon R. M., Averill M., Schwartz S. M., Giachelli C. M., Rosenfeld M. E., Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 9 2117 2124 2-s2.0-33747423277 10.1161/01.ATV.0000236428.91125. e6 (Pubitemid 44253797)
36. Price P. A., June H. H., Buckley J. R., Williamson M. K., Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 10 1610 1616 2-s2.0-0035723970 (Pubitemid 34215580)
37. Browner W. S., Lui L. Y., Cummings S. R., Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism 2001 86 2 631 637 2-s2.0-0035094860 10.1210/jc.86.2.631 (Pubitemid 32207471)
38. Flyvbjerg A., Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nature Reviews Endocrinology 2010 6 2 94 101 2-s2.0-76149143129 10.1038/nrendo.2009.266
39. Lieb W., Gona P., Larson M. G., Massaro J. M., Lipinska I., Keaney J. F., Rong J., Corey D., Hoffmann U., Fox C. S., Vasan R. S., Benjamin E. J., Odonnell C. J., Kathiresan S., Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 9 1849 1854 2-s2.0-77955983144 10.1161/ATVBAHA.109.199661
40. Mogelvang R., Pedersen S. H., Flyvbjerg A., Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. American Journal of Cardiology 2012 109 4 515 520
41. Yang Q., Lu S., Chen Y., Song X., Jin Z., Yuan F., Li H., Zhou Y., Chen F., Huo Y., Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. Clinical Cardiology 2011 34 7 447 453 2-s2.0-79960432072 10.1002/clc.20909
42. Hofbauer L. C., Schoppet M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Journal of the American Medical Association 2004 292 4 490 495 2-s2.0-3242781731 10.1001/jama.292.4.490 (Pubitemid 38988958)
43. Jensen J. K., Ueland T., Atar D., Gullestad L., Mickley H., Aukrust P., Januzzi J. L., Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. Journal of Internal Medicine 2010 267 4 410 417 2-s2.0-77949349542 10.1111/j.1365-2796.2009.02163.x
44. Pedersen E. R., Ueland T., Seifert R., Aukrust P., Schartum-Hansen H., Ebbing M., Bleie Ø., Igland J., Svingen G., Nordrehaug J. E., Nygård O., Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. Atherosclerosis 2010 212 2 644 649 2-s2.0-77957720102 10.1016/j.atherosclerosis.2010.06.027
45. Ueland T., Wilson S. G., Amirul Islam F. M., Mullin B., Devine A., Bollerslev J., Zhu K., Prince R. L., A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. Clinical Endocrinology 2009 71 6 828 833 2-s2.0-70449346293 10.1111/j.1365-2265.2009.03605.x
46. Semb A. G., Ueland T., Aukrust P., Wareham N. J., Luben R., Gullestad L., Kastelein J. J. P., Khaw K. T., Boekholdt S. M., Osteoprotegerin and soluble receptor activator of nuclear factor- B ligand and risk for coronary events: A nested case-control approach in the prospective EPIC-norfolk population study 1993-2003. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 6 975 980 2-s2.0-66349101657 10.1161/ATVBAHA.109.184101
47. Zagura M., Serg M., Kampus P., Zilmer M., Zilmer K., Eha J., Unt E., Lieberg J., Kals J., Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. American Journal of Hypertension 2010 23 6 586 591 2-s2.0-77952542901 10.1038/ajh.2010.38
48. Helske S., Kovanen P. T., Lindstedt K. A., Salmela K., Lommi J., Turto H., Werkkala K., Kupari M., Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. European Journal of Heart Failure 2007 9 4 357 363 2-s2.0-33947331531 10.1016/j.ejheart.2006.10.015 (Pubitemid 46441975)
49. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., Squire I. B., Gullestad L., Bollerslev J., Dickstein K., Aukrust P., Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology 2004 44 10 1970 1976 2-s2.0-8144227919 10.1016/j.jacc.2004.06.076 (Pubitemid 39473280)
50. Crisafulli A., Micari A., Altavilla D., Saporito F., Sardella A., Passaniti M., Raffa S., D'Anneo G., Lucà F., Mioni C., Arrigo F., Squadrito F., Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clinical Science 2005 109 4 389 395 2-s2.0-26844468811 10.1042/CS20050058 (Pubitemid 41445246)
51. Avignon A., Sultan A., Piot C., Mariano-Goulart D., Dit Dieudonné J. F. T., Cristol J. P., Dupuy A. M., Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007 30 11 2934 2939 2-s2.0-36048980895 10.2337/dc07-0992 (Pubitemid 350083147)
52. Rasmussen L. M., Tarnow L., Hansen T. K., Parving H. H., Flyvbjerg A., Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular mordibity in type 1 diabetic patients. European Journal of Endocrinology 2006 154 1 75 81 2-s2.0-32844472729 10.1530/eje.1.02049 (Pubitemid 43250739)
53. Blazquez-Medela A. M., Garcia-Ortiz L., Gomez-Marcos M. A., Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. European Journal of Clinical Investigation 2012 42 5 548 556
54. Davis P. H., Dawson J. D., Riley W. A., Lauer R. M., Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age the muscatine Study. Circulation 2001 104 23 2815 2819 2-s2.0-0035808024 (Pubitemid 33126656)
55. Nathan D. M., Long-term complications of diabetes mellitus. The New England Journal of Medicine 1993 328 23 1676 1685 2-s2.0-0027253061 10.1056/NEJM199306103282306 (Pubitemid 23157351)
56. Järvisalo M. J., Putto-Laurila A., Jartti L., Lehtimäki T., Solakivi T., Rönnemaa T., Raitakari O. T., Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002 51 2 493 498 2-s2.0-0036066930 (Pubitemid 34764808)
57. Altinova A. E., Toruner F., Akturk M., Bukan N., Yetkin I., Cakir N., Arslan M., Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation 2011 71 4 340 343 2-s2.0-79958858420 10.3109/00365513.2011.570868
58. Grauslund J., Rasmussen L. M., Green A., Sjølie A. K., Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? Scandinavian Journal of Clinical and Laboratory Investigation 2010 70 3 188 193 2-s2.0-77951429703 10.3109/00365511003653599
59. Golledge J., McCann M., Mangan S., Lam A., Karan M., Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004 35 7 1636 1641 2-s2.0-3042546950 10.1161/01.STR.0000129790.00318.a3 (Pubitemid 38823639)
60. Lundby-Christensen L., Almdal T. P., Carstensen B., Tarnow L., Wiinberg N., Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study. Cardiovascular Diabetology 2010 9, article 40
61. Poulsen M. K., Nybo M., Dahl J., Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovascular Diabetology 2011 10, article 76
62. Ishiyama M., Suzuki E., Katsuda J., Murase H., Tajima Y., Horikawa Y., Goto S., Fujita T., Takeda J., Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Research and Clinical Practice 2009 85 2 189 196 2-s2.0-67649836838 10.1016/j.diabres.2009. 04.023
63. Shin J. Y., Shin Y. G., Chung C. H., Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006 29 7 1664 1666 2-s2.0-33746445963 10.2337/dc06-0631 (Pubitemid 44127600)
64. Terekeci H. M., Senol M. G., Top C., Sahan B., Celik S., Sayan O., Kucukardali Y., Ipcioglu O., Cagiltay E., Oktenli C., Ozata M., Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Experimental and Clinical Endocrinology and Diabetes 2009 117 3 119 123 2-s2.0-62749159768 10.1055/s-0028-1085425
65. Vrachnis N., Augoulea A., Iliodromiti Z., Lambrinoudaki I., Sifakis S., Creatsas G., Previous gestational diabetes mellitus and markers of cardiovascular risk. International Journal of Endocrinology 2012 2012 6 10.1155/2012/458610 458610
66. Bo S., Valpreda S., Menato G., Bardelli C., Botto C., Gambino R., Rabbia C., Durazzo M., Cassader M., Massobrio M., Pagano G., Should we consider gestational diabetes a vascular risk factor? Atherosclerosis 2007 194 2 e72 e79 2-s2.0-34848841775 10.1016/j.atherosclerosis.2006.09.017 (Pubitemid 47513087)
67. Xiang A. H., Hodis H. N., Kawakubo M., Peters R. K., Kjos S. L., Marroquin A., Goico J., Ochoa C., Liu C. R., Liu C. H., Buchanan T. A., Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis 2008 199 1 207 214 2-s2.0-45249120586 10.1016/j.atherosclerosis.2007.10.016 (Pubitemid 351842700)
68. Tarim E., Yigit F., Kilicdag E., Bagis T., Demircan S., Simsek E., Haydardedeoglu B., Yanik F., Early onset of subclinical atherosclerosis in women with gestational diabetes mellitus. Ultrasound in Obstetrics and Gynecology 2006 27 2 177 182 2-s2.0-33646697955 10.1002/uog.2687 (Pubitemid 43733734)
69. Abdelghaffar S., El Amir M., El Hadidi A., El Mougi F., Carotid intima-media thickness: an index for subclinical atherosclerosis in type 1 diabetes. Journal of Tropical Pediatrics 2006 52 1 39 45 2-s2.0-31744437786 10.1093/tropej/fmi071 (Pubitemid 43174776)
70. Xiang G. D., Sun H. L., Zhao L. S., Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Research and Clinical Practice 2007 76 2 199 206 2-s2.0-33947142839 10.1016/j.diabres.2006. 09.008 (Pubitemid 46400128)